Skip to main content

Advertisement

SpringerLink
Log in

Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults

  • Review Article
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Due to increasing prevalence of intracranial device use and multidrug-resistant and nosocomial organisms, central nervous system (CNS) infections requiring treatment with intraventricular (IVT) aminoglycosides are becoming increasingly common. This article systematically reviews IVT aminoglycoside literature in adults and integrates available evidence to serve as a practical reference for clinicians. Medline (1946 to December 2015), Embase (1974 to December 2015), PubMed (1966 to December 2015), Google, and Google Scholar were searched using the term aminoglycoside combined individually with the terms IVT, meningitis, shunt infection, ventriculitis, and cerebral spinal fluid. Eighteen articles were included. IVT aminoglycosides were assessed in meningitis, ventriculitis, intracranial device infections and neurosurgery prophylaxis. No serious adverse effects following IVT aminoglycoside were reported. Dosages ranged from IVT gentamicin 4–10 mg daily, IVT tobramycin 5–10 mg daily, and IVT amikacin 5–50 mg daily. Duration of therapy should be individualized; however, continuing IVT antibiotics for 3 days and up to 21 days after cerebrospinal fluid (CSF) sterilization has been reported in literature. Most studies included concomitant intravenous antibiotic use. Therapeutic drug monitoring (TDM) was reported in five studies, with varying timing of CSF concentrations obtained. No clear relationship between CSF levels and efficacy or toxicity was evident. Based on current literature, IVT aminoglycosides for the treatment of sensitive gram-negative meningitis, ventriculitis, and CNS device-associated infections appear safe and effective. Optimal dosing regimens are unclear. It is reasonable to initiate IVT aminoglycoside at lowest dose in combination with IV therapy and continuing post CSF sterilization. Preservative-free formulations should be utilized to minimize adverse drug reactions. TDM should not be routinely utilized but reserved for more complicated patients. Further pharmacokinetic and clinical trials of IVT aminoglycosides are necessary to fill current therapeutic gaps. Due to the relatively limited cases of IVT aminoglycoside utilization, prospective, randomized, controlled trials are likely not feasible, and clinicians will have to rely on data from non-randomized and/or retrospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med. 2010;362:146–54.

    Article  PubMed  Google Scholar 

  2. Humphreys H, Jenks PJ. Surveillance and management of ventriculitis following neurosurgery. J Hosp Infect. 2015;89:281–6.

    Article  CAS  PubMed  Google Scholar 

  3. Beer R, Lackner P, Pfausler B, Schmutzhard E. Nosocomial ventriculitis and meningitis in neurocritical care patients. J Neurol. 2008;255:1617–24.

    Article  CAS  PubMed  Google Scholar 

  4. Ziai WC, Lewin JJ III. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol. 2009;22:277–82.

    Article  CAS  PubMed  Google Scholar 

  5. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84.

    Article  PubMed  Google Scholar 

  6. Ng K, Mabasa VH, Chow I, Ensom MHH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. Neurocrit Care. 2014;20:158–71.

    Article  CAS  PubMed  Google Scholar 

  7. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29:832–45.

    Article  CAS  PubMed  Google Scholar 

  8. Kaiser AB, McGee ZA. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med. 1975;293:1215–20.

    Article  CAS  PubMed  Google Scholar 

  9. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.

    Article  CAS  PubMed  Google Scholar 

  10. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal Fluid/Blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins; 1996.

    Google Scholar 

  12. Bruckner O, Collmann H, Trautmann M. Cefsulodin in the treatment of pseudomonas meningitis. Infection. 1983;11:264–8.

    Article  CAS  PubMed  Google Scholar 

  13. Mombelli G, Klastersky J, Coppens L, Daneau D, Nubourgh Y. Gram-negative bacillary meningitis in neurosurgical patients. J Neurosurg. 1983;59:634–41.

    Article  CAS  PubMed  Google Scholar 

  14. Kourtopoulos H, Holm SE. Intraventricular treatment of Serratia marcescens meningitis with gentamicin pharmacokinetic studies of gentamicin concentration in one case. Scand J Infect Dis. 1976;8:57–60.

    CAS  PubMed  Google Scholar 

  15. Chuang Y, Chang W, Lu C, Wu H, Chang H. Pseudomonas aeruginosa central nervous system infections: analysis of clinical features of 16 adult patients. Chin Med J. 1999;62:300–7.

    CAS  Google Scholar 

  16. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J Infect. 2005;50:348–52.

    Article  PubMed  Google Scholar 

  17. Marone P, Concia E, Maserati R, et al. Ceftazidime in the therapy of pseudomonal meningitis. Chemioterapia. 1985;4:289–92.

    CAS  PubMed  Google Scholar 

  18. Nunez ML, Martinez-Toldos MC, Bru M, Simarro E, Segovia M, Ruiz J. Appearance of resistance to meropenem during the treatment of a patient with meningitis by acinetobacter. Scand J Infect Dis. 1998;30:421–3.

    Article  CAS  PubMed  Google Scholar 

  19. Barnes BJ, Wiederhold NP, Micek ST, Polish LB, Ritchie DJ. Enterobacter cloacae ventriculitis successfully treated with cefepime and gentamicin: case report and review of the literature. Pharmacotherapy. 2003;23:537–42.

    Article  PubMed  Google Scholar 

  20. Wald SL, McLaurin RL. Cerebrospinal fluid antibiotic concentrations during treatment of shunt infections. J Neurosurg. 1980;52:41–6.

    Article  CAS  PubMed  Google Scholar 

  21. Archer GL, Tenenbaum MJ, Haywood HB 3rd. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA. 1978;25(240):751–3.

    Article  Google Scholar 

  22. Nevrekar S, Cunningham KC, Greathouse KM, Panos NG. Dual intraventricular plus systemic antibiotic therapy for the treatment of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae ventriculitis. Ann Pharmacother. 2014;48:274–8.

    Article  PubMed  Google Scholar 

  23. Patel JA, Pacheco SM, Postelnick M, Sutton S. Prolonged triple therapy for persistent multidrug-resistant Acinetobacter baumannii ventriculitis. Am J Health Syst Pharm. 2011;68:1527–31.

    Article  CAS  PubMed  Google Scholar 

  24. Zeidman SM, Geisler FH, Olivi A. Intraventricular rupture of a purulent brain abscess: case report. Neurosurgery. 1995;36:189–93.

    Article  CAS  PubMed  Google Scholar 

  25. Tangden T, Enblad P, Ullberg M, Sjolin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis. 2011;52:1310–6.

    Article  PubMed  Google Scholar 

  26. Wang J, Lin P, Chou C, et al. Intraventricular antimicrobial therapy in postneurosurgical gram-negative bacillary meningitis or ventriculitis: a hospital-based retrospective study. J Microbiol Immunol Infect. 2014;47:204–10.

    Article  CAS  PubMed  Google Scholar 

  27. Barriere SL, Conte JE Jr. Emergence of multiple antibiotic resistance during the therapy of Klebsiella pneumoniae meningitis. Am J Med Sci. 1980;279:61–5.

    Article  CAS  PubMed  Google Scholar 

  28. Ragel BT, Browd SR, Schmidt RH. Surgical shunt infection: significant reduction when using intraventricular and systemic antibiotic agents. J Neurosurg. 2006;105:242–7.

    Article  PubMed  Google Scholar 

  29. Collins JM. Pharmacokinetics of intraventricular administration. J Neurooncol. 1983;1:283–91.

    Article  CAS  PubMed  Google Scholar 

  30. Stenehjem E, Armstrong WS. Central nervous system device infections. Infect Dis Clin North Am. 2012;26:89–110.

    Article  PubMed  Google Scholar 

  31. Agrawal A, Cincu R, Timothy J. Current concepts and approach to ventriculitis. Infect Dis Clin Pract. 2008;16:100–4.

    Article  Google Scholar 

  32. Berk SL, Mccabe WR. Meningitis caused by gram-negative bacilli. Ann Intern Med. 1980;93:253–60.

    Article  CAS  PubMed  Google Scholar 

  33. Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98:1040–4.

    Article  CAS  PubMed  Google Scholar 

  34. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–283.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding was received for completion of this study or writing of the manuscript.

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Marlys LeBras & Mary H. H. Ensom

  2. Lower Mainland Pharmacy Services, Burnaby General Hospital, 3935 Kincaid Street, Burnaby, BC, V5G 2X6, Canada

    Ivy Chow & Vincent H. Mabasa

  3. Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada

    Mary H. H. Ensom

Authors
  1. Marlys LeBras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivy Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent H. Mabasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary H. H. Ensom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent H. Mabasa.

Ethics declarations

Conflict of Interest

The authors declare they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

LeBras, M., Chow, I., Mabasa, V.H. et al. Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults. Neurocrit Care 25, 492–507 (2016). https://doi.org/10.1007/s12028-016-0269-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-016-0269-3

Keywords

Search

Navigation